Nissan Chemical and Modulus Discovery Jointly Announce Signing of Strategic Drug Discovery Collaboration Agreement

On April 21, 2021 Nissan Chemical Corporation (Head Office: Chuo-ku, Tokyo Japan; President: Shinsuke Yagi, "Nissan Chemical"), and Modulus Discovery, Inc. (Head Office: Chiyoda-ku, Tokyo Japan; CEO: S. Roy Kimura, Ph.D., "Modulus"), an early stage global biopharmaceutical company, reported the signing of a strategic drug discovery collaboration agreement (Press release, Modulus Discovery, APR 21, 2021, View Source [SID1234578296]). Under this agreement, the companies will collaboratively accelerate the development of novel small molecule drug candidates derived from Modulus’ pipeline of R&D programs leveraging each party’s drug discovery platform and expertise.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nissan Chemical has been developing novel medicines through proprietary drug discovery research and drug substance development functions, and has built a track record of multiple drug candidate out-licensing deals and market approvals of innovative medicines. Modulus is a preclinical-stage technology-driven drug discovery firm leveraging its cutting-edge computational technology, accumulated disease biology insights, and a networked operational platform that enables accelerated and efficient identification of small molecule drug candidates. Modulus’ proprietary pipeline of programs are focused on chronic inflammatory diseases, oncology, immune disorders, and rare genetic conditions.

This strategic collaboration aims to accelerate several of Modulus’ late-stage discovery programs toward entry into clinical trials through Nissan Chemical’s technology and know-how on drug substance development and manufacturing and sharing of development costs. Nissan Chemical will receive a portion of the profits that Modulus obtains from future licensing deals for these programs.